LOG IN 
Event Overview
Share
Send to colleagueMeeting Overview
Join Dr Susan O’Brien and other international acute lymphoblastic leukemia (ALL) experts in Atlanta for a live, interactive satellite symposium titled Optimizing Management of Acute Lymphoblastic Leukemia: From Adolescents to Adults. Engage with the experts and your peers in discussions about contemporary best practices and new clinical trial evidence in ALL, including principles relating to diagnosis and risk and treatment response assessment, as well as selecting therapy in the settings of remission induction, consolidation, maintenance, and relapsed/refractory disease.
Friday satellite symposium on Optimizing Management of Acute Lymphoblastic Leukemia: From Adolescents to Adults preceding the 59th ASH Annual Meeting & Exposition
Date and Location
Friday, December 8, 2017
12.30 PM – 4.15 PM
International Ballroom North
Hyatt Regency Atlanta
265 Peachtree Street NE
Atlanta, Georgia 30303
Date/Time
Friday, December 8, 2017
12.30 PM – 4.15 PM
Location
Atlanta, Georgia, United States
CME
2.75 AMA PRA Category 1 Credits™
Friday, December 8, 2017
| 12.30 PM | Registration and lunch |
| 1.10 PM | Welcome and introduction Susan O’Brien, MD |
| 1.15 PM | Hematology guru: How well do you know ALL? Susan O’Brien, MD |
| 1.20 PM | Diagnosis and risk assessment of ALL Nicola Gökbuget, MD |
| 1.30 PM | Induction therapy for adults with ALL Nicola Gökbuget, MD |
| 1.50 PM | Induction therapy for adolescents/young adults (AYAs) with ALL Stephen E. Sallan, MD |
| 2.10 PM | Minimal residual disease and post-remission therapy Ching-Hon Pui, MD |
| 2.30 PM | Interactive exercise: Selecting initial treatments and managing toxicity for patients with ALL Nicola Gökbuget, MD |
| 2.40 PM | Break |
| 3.00 PM | Current strategies for relapsed/refractory ALL in AYAs and adults: Where we are now Eunice Wang, MD |
| 3.20 PM | Emerging and novel therapies in ALL: What’s on the horizon? Susan O’Brien, MD |
| 3.45 PM | Interactive exercise: Selecting treatment for relapsed/refractory disease Eunice Wang, MD |
| 3.55 PM | Faculty panel discussion/audience participation Susan O’Brien, MD (Moderator) |
| 4.10 PM | prIME Points™ Susan O’Brien, MD |
| 4.15 PM | Adjourn |
-
Susan O'Brien, MDUC Irvine Health
Chao Family Comprehensive Cancer Center
Orange, California, United States -
Nicola Gökbuget, MDGoethe University
Frankfurt, Germany -
Ching-Hon Pui, MDSt Jude Children’s Research Hospital
Memphis, Tennessee, United States -
Stephen E. Sallan, MDDana-Farber Cancer Institute
Boston, Massachusetts, United States -
Eunice Wang, MDRoswell Park Cancer Institute
Buffalo, New York, United States
CHAIR
FACULTY
Target Audience
The activity is specifically designed to meet the needs of medical oncologists, hematologists, and other healthcare professionals involved in the treatment of AYA and adult patients with ALL.
Learning Objectives
After successful completion of this educational activity, participants should be able to:
- Interpret patient- and disease-related factors to accurately diagnose and assess risk in AYAs and adults with ALL
- Describe the role of assessing minimal residual disease in both the prognosis and treatment planning for AYAs and adults with ALL
- Design optimal induction strategies for the initial treatment of AYAs and adults with ALL
- Develop optimal strategies for relapsed/refractory ALL in the AYA and adult populations
- Analyze the role of new and emerging therapies used to treat ALL in AYAs and adults
Support
This educational activity is supported by grants from Amgen and Shire.
Continuing Education
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
prIME Oncology designates this live activity for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Provider
This activity is provided by prIME Oncology.
Sunshine Act/EFPIA Disclosure Code
prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.
Disclosures
Disclosure of Relevant Financial Relationships
prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.